Javascript must be enabled to continue!
Immediate Effect of Intravitreal Bevacizumab Injection on Intraocular Pressure
View through CrossRef
Purpose: Raised intra ocular pressure following intravitreal Bevacizumabis a potential side effect which can be clinically significant. The aim of the study was to evaluate short term changes in intraocular pressure after intravitreal Bevacizumab injection.
Study Design: Quasi experimental study.
Place and Duration of Study: Benazir Bhutto Hospital, Rawalpindi from January 2021 to July 2021.
Methods: This study includes 88 eyes of 88 patients who received intravitreal Bevacizumab injection. Both females and males between the ages of 10 and 80 years, with any indication for intravitreal Bevacizumab, were included. Intraocular pressure (IOP) was measured before injection, immediately after injection at 0 minutes, at 30 minutes and at 60 minutes. Paired t test was used to compare post injection changes in IOP from baseline.
Results: All except one eye recoded increase in IOP immediately after injection. It returned to normal range in35 (39.8%) eyes at 30 minutes and at 60 minutes 78 (88.6%) eyes had normal IOP. Highest mean IOP was recorded immediately after injection which was 30.89+5.648and that reduced to 23.08+4.516 at 30 minutes and 18.14+2.623 at 60 minutes. Paired t test showed that the changes were significantly higher from baseline 13.30+2.78 at these intervals after injection.
Conclusion: An increase in intraocular pressure after intravitreal Bevacizumab injection is a frequent occurrence; however, for the majority of patients, it is transient and returns to normal levels within one hour.
Ophthalmological Society of Pakistan
Title: Immediate Effect of Intravitreal Bevacizumab Injection on Intraocular Pressure
Description:
Purpose: Raised intra ocular pressure following intravitreal Bevacizumabis a potential side effect which can be clinically significant.
The aim of the study was to evaluate short term changes in intraocular pressure after intravitreal Bevacizumab injection.
Study Design: Quasi experimental study.
Place and Duration of Study: Benazir Bhutto Hospital, Rawalpindi from January 2021 to July 2021.
Methods: This study includes 88 eyes of 88 patients who received intravitreal Bevacizumab injection.
Both females and males between the ages of 10 and 80 years, with any indication for intravitreal Bevacizumab, were included.
Intraocular pressure (IOP) was measured before injection, immediately after injection at 0 minutes, at 30 minutes and at 60 minutes.
Paired t test was used to compare post injection changes in IOP from baseline.
Results: All except one eye recoded increase in IOP immediately after injection.
It returned to normal range in35 (39.
8%) eyes at 30 minutes and at 60 minutes 78 (88.
6%) eyes had normal IOP.
Highest mean IOP was recorded immediately after injection which was 30.
89+5.
648and that reduced to 23.
08+4.
516 at 30 minutes and 18.
14+2.
623 at 60 minutes.
Paired t test showed that the changes were significantly higher from baseline 13.
30+2.
78 at these intervals after injection.
Conclusion: An increase in intraocular pressure after intravitreal Bevacizumab injection is a frequent occurrence; however, for the majority of patients, it is transient and returns to normal levels within one hour.
Related Results
Reflux after intravitreal injection: an anterior segment optical coherence tomography study
Reflux after intravitreal injection: an anterior segment optical coherence tomography study
Purpose: To investigate the intraocular pressure and conjunctival thickness changes following the intravitreal injection Methods: Sixty eyes of 60 patients having intravitreal inj...
Abstract 2099: Model-riven optimization of anti-angiogenics combined with chemotherapy: application to bevacizumab + pemetrexed/cisplatin doublet in NSCLC-bearing mice
Abstract 2099: Model-riven optimization of anti-angiogenics combined with chemotherapy: application to bevacizumab + pemetrexed/cisplatin doublet in NSCLC-bearing mice
Abstract
Bevacizumab-containing protocols are all based upon the concomitant administration of the drugs given in a row. Bevacizumab is expected to induce a transien...
Effect of Intravitreal Anti-Vascular Endothelial Growth Factor Injection on Intraocular Pressure and Systemic Blood Pressure
Effect of Intravitreal Anti-Vascular Endothelial Growth Factor Injection on Intraocular Pressure and Systemic Blood Pressure
Objective: To determine the effect of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure and systemic blood pressure in the immediate post-inje...
Intravitreal brimonidine inhibits form-deprivation myopia in guinea pigs
Intravitreal brimonidine inhibits form-deprivation myopia in guinea pigs
Abstract
Background
The use of ocular hypotensive drugs has been reported to attenuate myopia progression. This study explores whether brimonidine c...
Effect of intravitreal bevacizumab injection in central serous chorioretinopathy
Effect of intravitreal bevacizumab injection in central serous chorioretinopathy
AbstractPurposeTo investigate the effect of intravitreal bevacizumab injection on the type of central serous chorioretinopathy.MethodsWe performed a retrospective analysis of 43 pa...
Overview of Key Zonal Water Injection Technologies in China
Overview of Key Zonal Water Injection Technologies in China
Abstract
Separated layer water injection is the important technology to realize the oilfield long-term high and stable yield. Through continuous researches and te...
99mTc-Labeled Bevacizumab via HYNIC for Imaging of Melanoma
99mTc-Labeled Bevacizumab via HYNIC for Imaging of Melanoma
Vascular endothelial growth factor (VEGF) is one of the classic factors to tumour-induced angiogenesis in several types, including melanoma. Bevacizumab, a monoclonal antibody ant...
The Auckland Endophthalmitis Study
The Auckland Endophthalmitis Study
Purpose: To report on the incidence and management of endophthalmitis following intravitreal bevacizumab in Auckland, New Zealand. Method: A survey of facilities in Auckland perfor...


